<?xml version="1.0" encoding="UTF-8"?>
<feed xmlns="http://www.w3.org/2005/Atom"  xmlns:media="http://search.yahoo.com/mrss/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd" xmlns:geo="http://www.w3.org/2003/01/geo/wgs84_pos#" xmlns:georss="http://www.georss.org/georss" xmlns:photo="http://www.pheed.com/pheed/">
 <title>Daily CSR</title>
 <subtitle><![CDATA[Daily CSR delivers latest news and in-depth coverage about corporate social responsibility, ethics and sustainability]]></subtitle>
 <link rel="alternate" type="text/html" href="https://www.dailycsr.com" />
 <link rel="self" type="text/xml" href="https://www.dailycsr.com/xml/atom.xml" />
 <id>https://www.dailycsr.com/</id>
 <updated>2026-06-05T12:21:51+02:00</updated>
 <generator uri="http://www.wmaker.net">Webzine Maker</generator>
  <icon>https://www.dailycsr.com/favicon.ico</icon>
  <entry>
   <title>Gifthealth Wins Platinum for Top Digital Health Platform at Pinnacle Awards 2026</title>
   <updated>2026-04-24T14:16:00+02:00</updated>
   <id>https://www.dailycsr.com/Gifthealth-Wins-Platinum-for-Top-Digital-Health-Platform-at-Pinnacle-Awards-2026_a5743.html</id>
   <category term="Companies" />
   <photo:imgsrc>https://www.dailycsr.com/photo/art/imagette/96229645-67131608.jpg</photo:imgsrc>
   <published>2026-04-24T14:13:00+02:00</published>
   <author><name>Debashish Mukherjee</name></author>
   <content type="html">
    <![CDATA[
     <div style="position:relative; text-align : center; padding-bottom: 1em;">
      <img src="https://www.dailycsr.com/photo/art/default/96229645-67131608.jpg?v=1777032970" alt="Gifthealth Wins Platinum for Top Digital Health Platform at Pinnacle Awards 2026" title="Gifthealth Wins Platinum for Top Digital Health Platform at Pinnacle Awards 2026" />
     </div>
     <div>
      <div style="text-align: justify;">Gifthealth, a patient access platform that streamlines the prescription journey from provider to patient, has received the Platinum award for Top Digital Health Platform at the 2026 Pinnacle Awards. <br />   <br />  As the leading direct-to-patient (DTP) partner for pharmaceutical companies, Gifthealth is known for advancing digital-first brand experiences. Its unified platform connects life sciences innovations directly with patients through automated prescription routing, transparent real-time pricing, and engagement across multiple channels. <br />   <br />  The recognition highlights Gifthealth’s role in reshaping the prescription experience into a smooth, patient-focused process—bridging manufacturers, healthcare providers, and patients in ways traditional systems have not achieved. <br />   <br />  “We don’t take our mission lightly when we say we’re transforming the system,” said CEO Chip Parkinson. “We are fully committed to delivering bold solutions for our clients, partners, and every patient who depends on us. The responsibility is significant, but it fuels our drive to turn challenges into meaningful outcomes and better healthcare experiences.” <br />   <br />  Today, more than 175,000 prescribers rely on Gifthealth to help patients access medications more quickly and maintain adherence. With over six million completed patient journeys, the company is the first to successfully scale DTP delivery. Its Digi+Hub model has set new performance benchmarks, including:</div>    <ul>  	<li style="text-align: justify;">Dispense rates 50% above industry norms</li>  	<li style="text-align: justify;">Refill success rates 1.5 times the national average</li>  	<li style="text-align: justify;">50% lower abandonment rates</li>  	<li style="text-align: justify;">92% patient persistence compared to a 60% national benchmark</li>  	<li style="text-align: justify;">Customer satisfaction scores of 90%, versus 77% industry-wide</li>  	<li style="text-align: justify;">95% of prescriptions delivered within one day, compared to six days nationally</li>  </ul>    <div style="text-align: justify;">“Healthcare is evolving faster than ever, and this year’s winners exemplify excellence in innovation, empathy, and measurable impact,” said Kate Lang, Executive Director of the Pinnacle Awards. “From AI-powered diagnostics to patient-centric care delivery, these organizations are redefining the future of global healthcare.” <br />   <br />  Click <a class="link" href="https://www.gifthealth.com/">here</a>  to learn more about how Gifthealth provides a scalable and proven model that brings direct-to-patient solutions to life.</div>  
     </div>
     <br style="clear:both;"/>
    ]]>
   </content>
   <link rel="alternate" href="https://www.dailycsr.com/Gifthealth-Wins-Platinum-for-Top-Digital-Health-Platform-at-Pinnacle-Awards-2026_a5743.html" />
  </entry>
  <entry>
   <title>Intensity Therapeutics Wins 2026 Pinnacle Award for INT230-6 Cancer Therapy</title>
   <updated>2026-04-16T16:34:00+02:00</updated>
   <id>https://www.dailycsr.com/Intensity-Therapeutics-Wins-2026-Pinnacle-Award-for-INT230-6-Cancer-Therapy_a5715.html</id>
   <category term="Companies" />
   <photo:imgsrc>https://www.dailycsr.com/photo/art/imagette/96078905-67029767.jpg</photo:imgsrc>
   <published>2026-04-16T16:32:00+02:00</published>
   <author><name>Debashish Mukherjee</name></author>
   <content type="html">
    <![CDATA[
     <div style="position:relative; text-align : center; padding-bottom: 1em;">
      <img src="https://www.dailycsr.com/photo/art/default/96078905-67029767.jpg?v=1776350087" alt="Intensity Therapeutics Wins 2026 Pinnacle Award for INT230-6 Cancer Therapy" title="Intensity Therapeutics Wins 2026 Pinnacle Award for INT230-6 Cancer Therapy" />
     </div>
     <div>
      <div style="text-align: justify;">&nbsp;</div>    <p style="text-align: justify;">Intensity Therapeutics, Inc., a late-stage biotechnology firm, focuses on discovering and developing proprietary cancer treatments using its non-covalent drug-conjugation technology. This approach is designed to destroy tumors while enhancing the immune system’s ability to recognize cancer. The company has been named a winner at the 2026 Pinnacle Awards for Healthcare for its intratumoral injection platform and its leading drug candidate, INT230-6. <br />    <p style="text-align: justify;">The company earned a Platinum award in the Innovator in Biotech Solutions category. INT230-6, Intensity’s primary investigational therapy, is intended for direct injection into tumors. It combines two well-established anticancer drugs—cisplatin and vinblastine sulfate—with a diffusion and cell penetration enhancer known as SHAO. This component enables the drugs to spread more effectively throughout tumors and enter cancer cells more efficiently. INT230-6 is currently being developed alongside standard treatment approaches to enhance long-term responses across a range of solid tumor types. <br />    <p style="text-align: justify;">According to co-founder and CEO Lewis H. Bender, the Pinnacle Award recognition highlights the company’s dedication to transforming cancer treatment. He noted that INT230-6 introduces a novel mechanism for inducing cancer cell death, with the potential to shift cancer from an acute, often fatal condition to a manageable chronic disease, even in cases that do not respond to immunotherapy. <br />    <p style="text-align: justify;">The Pinnacle Awards is a respected annual program that honors excellence across multiple industries. It recognizes organizations, products, and individuals that demonstrate significant innovation, creativity, and impact. Each year, candidates are assessed by a panel of industry experts, media professionals, and consultants to ensure that only the most deserving recipients are selected. <br />  
     </div>
     <br style="clear:both;"/>
    ]]>
   </content>
   <link rel="alternate" href="https://www.dailycsr.com/Intensity-Therapeutics-Wins-2026-Pinnacle-Award-for-INT230-6-Cancer-Therapy_a5715.html" />
  </entry>
</feed>
